ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study protocol

BMC Ophthalmology

Volumn 11, Issue 1, 2011, Pages

  Bochmann, Frank ^a   Kaufmann, Claude ^a   Becht, Christoph N ^a   Guber, Ivo ^a   Kaiser, Michael ^a   Bachmann, Lucas M ^a   Thiel, Michael A ^a  

^a LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; MITOMYCIN; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A;

ARTICLE; CLINICAL TRIAL; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG ANTAGONISM; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LENS IMPLANTATION; METHODOLOGY; PATHOPHYSIOLOGY; PHACOEMULSIFICATION; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SUTURE; TRABECULECTOMY; TREATMENT OUTCOME; WOUND HEALING;

ANTIBODIES, MONOCLONAL; CONJUNCTIVA; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LENS IMPLANTATION, INTRAOCULAR; MITOMYCIN; OPHTHALMIC SOLUTIONS; PHACOEMULSIFICATION; POSTOPERATIVE PERIOD; RESEARCH DESIGN; SUTURES; TRABECULECTOMY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 78651380956     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-11-1     Document Type: Article

References (26)

1. Trabeculectomy. Preliminary report of a new method. JE Cairns, Am J Ophthalmol 1968 66 4 673 679 4891876
2. Five-year follow-up of the Fluorouracil Filtering Surgery Study. The Fluorouracil Filtering Surgery Study Group. Am J Ophthalmol 1996 121 4 349 366 8604728
3. Five-year results of trabeculectomy with mitomycin C. HJ Beckers KC Kinders CA Webers, Graefes Arch Clin Exp Oph (Pubitemid 36747797)
4. The effect of mitomycin C trabeculectomy on the progression of visual field defect in normal-tension glaucoma. Y Hagiwara T Yamamoto Y Kitazawa, Graefes Arch Clin Exp Ophthalmol 2000 238 3 232 236 10.1007/s004170050349 10796038 (Pubitemid 30197960)
5. Outcomes of primary phakic trabeculectomies without versus with 0.5- to 1-minute versus 3- to 5-minute mitomycin C. YY Kim RM Sexton DH Shin C Kim SA Ginde J Ren D Lee TH Kupin, Am J Ophthalmol 1998 126 6 755 762 10.1016/S0002-9394(98)00279-7 9859998 (Pubitemid 29004418)
6. Histopathology of episcleral fibrosis after trabeculectomy with and without mitomycin C. H Mietz G Arnold B Kirchhof M Diestelhorst GK Krieglstein, Graefes Arch Clin Exp Ophthalmol 1996 234 6 364 368 10.1007/BF00190712 8738702 (Pubitemid 26150818)
7. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. D WuDunn LB Cantor AM Palanca-Capistrano J Hoop NP Alvi C Finley V Lakhani A Burnstein SL Knotts, Am J Ophthalmol 2002 134 4 521 528 10.1016/S0002-9394(02)01627-6 12383808 (Pubitemid 35304641)
8. Inhibition of corneal epithelial wound healing. A comparative study of mitomycin C and 5-fluorouracil. H Ando T Ido Y Kawai T Yamamoto Y Kitazawa, Ophthalmology 1992 99 12 1809 1814 1480395 (Pubitemid 23014346)
9. T lymphocyte mediated lysis of mitomycin C treated Tenon's capsule fibroblasts. JG Crowston LH Chang JT Daniels PT Khaw AN Akbar, Br J Ophthalmol 2004 88 3 399 405 10.1136/bjo.2002.007708 14977777 (Pubitemid 38333722)
10. In vivo confocal microscopy of filtering blebs after trabeculectomy. EM Messmer DM Zapp MJ Mackert M Thiel A Kampik, Arch Ophthalmol 2006 124 8 1095 1103 10.1001/archopht.124.8.1095 16908811 (Pubitemid 44232338)
11. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. J Tran J Rak C Sheehan SD Saibil E LaCasse RG Korneluk RS Kerbel, Biochem Biophys Res Commun 1999 264 3 781 788 10.1006/bbrc.1999.1589 10544009
12. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity. M Fujiwara Y Muragaki A Ooshima, Arch Dermatol Res 2005 297 4 161 169 10.1007/s00403-005-0596-2 16184401 (Pubitemid 41545630)
13. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. WS Wu FS Wang KD Yang CC Huang YR Kuo, J Invest Dermatol 2006 126 6 1264 1271 10.1038/sj.jid.5700274 16575391 (Pubitemid 43997906)
14. TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts. N Asano-Kato K Fukagawa N Okada T Kawakita Y Takano M Dogru K Tsubota H Fujishima, Exp Eye Res 2005 80 4 555 560 10.1016/j.exer.2004.11.006 15781283 (Pubitemid 40387524)
15. Modulation of human fibroblast activity by selected angiogenesis inhibitors. J Wong N Wang JW Miller JS Schuman, Exp Eye Res 1994 58 4 439 451 10.1006/exer.1994.1037 7523160 (Pubitemid 24171654)
16. Managing patients treated with bevacizumab combination therapy. MS Gordon D Cunningham, Oncology 2005 69 Suppl 3 25 33 10.1159/000088481 16301833 (Pubitemid 41680950)
17. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. FA Scappaticci L Fehrenbacher T Cartwright JD Hainsworth W Heim J Berlin F Kabbinavar W Novotny S Sarkar H Hurwitz, J Surg Oncol 2005 91 3 173 180 10.1002/jso.20301 16118771 (Pubitemid 41254420)
18. Needle bleb revision of encapsulated filtering bleb with bevacizumab. MY Kahook JS Schuman RJ Noecker, Ophthalmic Surg Lasers Imaging 2006 37 2 148 150 16583638
19. Topical bevacizumab therapy for corneal neovascularization. JJ DeStafeno T Kim, Arch Ophthalmol 2007 125 6 834 836 10.1001/archopht.125.6.834 17562998 (Pubitemid 46919748)
20. Intravitreal bevacizumab in a patient with neovascular glaucoma. MY Kahook JS Schuman RJ Noecker, Ophthalmic Surg Lasers Imaging 2006 37 2 144 146 16583637
21. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. S Michels PJ Rosenfeld CA Puliafito EN Marcus AS Venkatraman, Ophthalmology 2005 112 6 1035 1047 10.1016/j.ophtha.2005.02.007 15936441 (Pubitemid 40797459)
22. Testing intravitreal toxicity of bevacizumab (Avastin). RP Manzano GA Peyman P Khan M Kivilcim, Retina 2006 26 3 257 261 10.1097/00006982-200603000- 00001 16508423 (Pubitemid 44318176)
23. Ranibizumab for neovascular age-related macular degeneration. PJ Rosenfeld DM Brown JS Heier DS Boyer PK Kaiser CY Chung RY Kim, N Engl J Med 2006 355 14 1419 1431 10.1056/NEJMoa054481 17021318 (Pubitemid 44511557)
24. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. PJ Rosenfeld SD Schwartz MS Blumenkranz JW Miller JA Haller JD Reimann WL Greene N Shams, Ophthalmology 2005 112 6 1048 1053 10.1016/j.ophtha.2005.01.043 15885778 (Pubitemid 40797460)
25. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. J Gaudreault D Fei J Rusit P Suboc V Shiu, Invest Ophthalmol Vis Sci 2005 46 2 726 733 10.1167/iovs.04-0601 15671306 (Pubitemid 40270359)
26. (Pubitemid 28460020)